{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:30:54Z","timestamp":1760236254625,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["154126"],"award-info":[{"award-number":["154126"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The CanREValue Collaboration established the Reassessment &amp; Uptake Working Group to develop a preliminary process to reassess funded cancer drugs in Canada. A simulated exercise was conducted to evaluate the proposed reassessment process using a real-world case. We invited 32 attendees including representatives from Health Canada and Health Technology Assessment (HTA) agencies, along with payers, clinicians, academics, and patient representatives. A case was developed using a real-world study on a publicly funded cancer drug. In facilitated group sessions, participants were asked to deliberate upon the evidence presented in the case to issue reassessment recommendations. Several themes were identified through the deliberation discussions. While the generalizability of real-world evidence (RWE) is perceived as a strength, trust in the RWE depends largely on the source of the real-world data. The attendees suggested several improvements to the proposed reassessment process including evidence requirement for reassessment, recommendation categories, and a priori study protocols. This exercise generated important insights on the evidence required for conducting reassessment and considerations for improvements of the proposed reassessment process. Building upon lessons from this exercise, future work would continue to refine the reassessment process as part of the overall CanREValue framework.<\/jats:p>","DOI":"10.3390\/curroncol28060392","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T08:10:22Z","timestamp":1636704622000},"page":"4645-4654","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise"],"prefix":"10.3390","volume":"28","author":[{"given":"Wei","family":"Dai","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Craig","sequence":"additional","affiliation":[{"name":"New Brunswick Cancer Network, Fredericton, NB E3B 5G8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Fraser","sequence":"additional","affiliation":[{"name":"Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Chambers","sequence":"additional","affiliation":[{"name":"Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-3729","authenticated-orcid":false,"given":"Helen","family":"Mai","sequence":"additional","affiliation":[{"name":"Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Philosophy Department, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Earle","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Ontario Health (CCO), Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Geirnaert","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Taylor","sequence":"additional","affiliation":[{"name":"BC Cancer, Kelowna, BC V1Y 5L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Trudeau","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sperber","sequence":"additional","affiliation":[{"name":"Pan-Canadian Pharmaceutical Alliance, Toronto, ON M5S 2B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Beca","sequence":"additional","affiliation":[{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada"},{"name":"Ontario Health (CCO), Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-0742","authenticated-orcid":false,"given":"Avram","family":"Denburg","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-7797","authenticated-orcid":false,"given":"Rebecca","family":"Mercer","sequence":"additional","affiliation":[{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada"},{"name":"Ontario Health (CCO), Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambica","family":"Parmar","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":false,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Women\u2019s College Hospital, Toronto, ON M53 1B2, Canada"},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M53 3M2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pam","family":"Takhar","sequence":"additional","affiliation":[{"name":"Ontario Health (CCO), Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Chan","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada"},{"name":"Ontario Health (CCO), Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the CanREValue Collaboration","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2016.12.010","article-title":"The HTA Core Model\u00ae\u201410 Years of Developing an International Framework to Share Multidimensional Value Assessment","volume":"20","author":"Kristensen","year":"2017","journal-title":"Value Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"The new definition of health technology assessment: A milestone in international collaboration","volume":"36","author":"Schuller","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0266462312000359","article-title":"Health technology reassessment: Scope, methodology, & language","volume":"28","author":"Noseworthy","year":"2012","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205031211770486","DOI":"10.1177\/2050312117704861","article-title":"Achieving optimal technology use: A proposed model for health technology reassessment","volume":"5","author":"Soril","year":"2017","journal-title":"SAGE Open Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.9778\/cmajo.20170144","article-title":"The economic burden of cancer care in Canada: A population-based cost study","volume":"6","author":"Weir","year":"2018","journal-title":"CMAJ Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"ref_7","first-page":"e746","article-title":"Real-World Evidence in Oncology: Opportunities and Limitations","volume":"25","author":"Perrone","year":"2019","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7365\/JHPOR.2015.2.3","article-title":"Adoption of Real World Evidence in Decision-Making Processes on Public Funding of Drugs in Poland","volume":"2","author":"Wilk","year":"2015","journal-title":"J. Health Policy Outcomes Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/cer-2018-0066","article-title":"Real-world evidence for coverage decisions: Opportunities and challenges","volume":"7","author":"Hampson","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.18632\/oncotarget.27077","article-title":"Real-world evidence to guide healthcare policies in oncology","volume":"10","author":"Donia","year":"2019","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e032884","DOI":"10.1136\/bmjopen-2019-032884","article-title":"Developing a framework to incorporate real-world evidence in cancer drug funding decisions: The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration","volume":"10","author":"Chan","year":"2020","journal-title":"BMJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.3390\/curroncol28050354","article-title":"Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration\u2019s Reassessment and Uptake Working Group","volume":"28","author":"Dai","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_13","unstructured":"CADTH (2021, October 09). Procedures for the CADTH Pan-Canadian Oncology Drug Review. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pCODR%27s%20Drug%20Review%20Process\/pcodr-procedures.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Beca, J.M., Dai, W.F., Pataky, R.E., Tran, D., Dvorani, E., Isaranuwatchai, W., Peacock, S., Alvi, R., Cheung, W.Y., and Earle, C.C. (2021). Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clin. Oncol.","DOI":"10.1016\/j.clon.2021.08.009"},{"key":"ref_15","unstructured":"Tran, D. (2019, January 27\u201328). Real-world effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: Population-based retrospective cohort studies in three provinces. Proceedings of the 2019 ARCC Conference, Halifax, NS, Canada."},{"key":"ref_16","first-page":"23814683211021060","article-title":"Real-World Cost-Effectiveness of Bevacizumab with First-Line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces","volume":"6","author":"Pataky","year":"2021","journal-title":"MDM Policy Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"24966","DOI":"10.3402\/jmahp.v3.24966","article-title":"A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments","volume":"3","author":"Massetti","year":"2015","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_18","unstructured":"Patented Medicine Prices Review Board (2021, October 09). Working Group to Inform the Patented Medicine Prices Review Board (PMPRB) Steering Committee on Modernization of Price Review Process Guidelines. Available online: http:\/\/www.pmprb-cepmb.gc.ca\/CMFiles\/Consultations\/new_guidelines\/final-report-en.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1017\/S0266462313000494","article-title":"Health technology reassessment: The art of the possible","volume":"29","author":"MacKean","year":"2013","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"C\u00e1, V., Id, P., Ot\u00e1, J., Id, M.B., Assis, F., and Neves, R. (2019). Health technology reassessment in the Brazilian public health system: Analysis of the current status. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220131"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12961-016-0152-x","article-title":"A systematic review on current status of health technology reassessment: Insights for South Korea","volume":"14","author":"Seo","year":"2016","journal-title":"Health Res. Policy Syst."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1017\/S0266462312000438","article-title":"Health technology reassessment of non-drug technologies: Current practices","volume":"28","author":"Leggett","year":"2012","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1017\/S0266462320000252","article-title":"Sustainability of healthcare systems in Asia: Exploring the roles of horizon scanning and reassessment in the health technology assessment landscape","volume":"36","author":"Mundy","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40273-015-0293-8","article-title":"Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review","volume":"33","author":"Parkinson","year":"2015","journal-title":"PharmacoEconomics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"d4519","DOI":"10.1136\/bmj.d4519","article-title":"Disinvestment from low value clinical interventions: NICEly done?","volume":"343","author":"Garner","year":"2011","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1017\/S0266462320000628","article-title":"Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward","volume":"36","author":"Lou","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:29:20Z","timestamp":1760167760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["curroncol28060392"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28060392","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,11,12]]}}}